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Abstract 
Serum stimulation of human diploid fibroblast IMR-90 cells leads to phosphorylation f p33 cDx2 at Thrl60 and activation of CDK2 
kinase, a necessary event for G1/S transition. We report hat serum stimulation causes a gradual, sustained increase in the activity of 
CDK-activating kinase (CAK) that phosphorylates CDK2 at Thrl60, which starts by 5 h after serum stimulation and reaches the maximal 
plateau level at around the G]./S boundary. In this cell type addition of phorbol-12, 13-dibutyrate 5 h but not 16 h after serum stimulation 
completely inhibits CDK2 kinase activation and DNA synthesis. Phorbol ester treatment does not reduce the protein level of p33 cDK2, but 
does inhibit serum-stimulated increases in the CAK activity and CDK2 phosphorylation atThrl60. The suppression of the CAK activity 
by the phorbol ester is accompanied by decreases in the message levels of both CDK7 and cyclin H, the catalytic and the positive 
regulatory subunit of CAK, respectively. These results indicate that in IMR-90 cells activation of protein kinase C in the late G1 phase 
causes cell cycle arrest before the G1/S boundary at least in part through downregulation of CAK and CAK-mediated CDK2 
phosphorylation a d activation. 
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I. Introduction 
Eukaryotic ell cycle is driven by an ordered activation 
of a family of protein kinases, cyclin-dependent kinases, 
which are composed of a catalytic subunit CDK and a 
positive regulatory subunit cyclin [1,2]. Each CDK/cyclin 
complex is considered to play specialized roles at a de- 
fined stage of cell cycle, through phosphorylation of its 
specific, though largely unknown, substrate proteins [3-6]. 
Accumulating evidence indicates that CDK2/cyclin A 
complex mediates initiation and progression of the S phase 
[5,7-13]. Indeed, CDK2-associated protein kinase activity 
starts to increase just before the G1/S  boundary and 
continues to rise as cells progress through the S phase 
[7,8]. It has also been dentonstrated that microinjection of 
antibodies against CDK2 or cyclin A, or antisense cyclin A 
expression vector prevems serum-stimulated cells from 
entering into the S phase [9-13]. Activation of CDK2 
depends on both assembly with a cyclin molecule (cyclin 
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E in the late G1 phase and cyclin A in the S phase) and 
phosphorylation of CDK2 at Thrl60 [14,15]. Recently, 
CDK activating kinase (CAK), that phosphorylates CDK2 
at Thr160 and activates CDK2, has been identified [ 16-22]. 
It has been proved that CAK itself is a CDK/cycl in 
complex composed of the catalytic subunit CDK7 (homo- 
logue of Xenopus MO15) [16-19] and a novel cyclin, 
cyclin H [20,21]. CDK7 (MO15) possesses structural fea- 
tures common to CDK family kinases, including a putative 
activating phosphorylation site which corresponds to 
Thrl60 of CDK2 [16-19,22]. These recent findings indi- 
cate that the CAK-CDK2 kinase cascade plays a pivotal 
role in cell cycle traverse across the G1/S  border. 
Protein kinase C (PKC) has been implicated as one of 
the major regulators of cell growth and proliferation. Ear- 
lier studies demonstrated that activators of PKC, including 
tumor-promoting phorbol esters and diacylglycerol ana- 
logues, stimulate DNA synthesis in some cell types [23,24]. 
It was later shown, however, that under certain circum- 
stances PKC activation rather causes inhibition of cell 
growth [8,25-27]. We have recently demonstrated in hu- 
man umbilical vein endothelial cells that the major molec- 
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ular target of inhibitory action of PKC is located in the 
later half of the G1 phase. Thus, the addition of the PKC 
activator phorbol-12, 13-dibutyrate (PDBu) or 1,2-dioc- 
tanoylglycerol in the late GI phase, but not during the 
early G1 phase or in the S phase, results in complete 
inhibition of growth factor-induced CDK2 activation and 
initiation of DNA synthesis [8]. The effects of the PKC 
activators are nearly totally abolished in phorbol ester-pre- 
treated, PKC-down-regulated ndothelial cells [8]. We have 
further shown that the PKC activation in the late G 1 phase 
results in complete suppression of growth factor-induced 
increases in the mRNA level of cyclins A and E, but not 
CDK2 [8,28]. We have subsequently found that the growth 
inhibitory mode of PKC action is not confined to endothe- 
lial cells but is also observed in human diploid fibroblasts 
IMR-90. In the present study, to explore in depth the 
molecular mechanism by which PKC inhibits the activa- 
tion of CDK2, we examined the regulation by PKC of 
CAK-mediated phosphorylation of CDK2 at Thrl60 in 
IMR-90 cells. We report here that the PKC activation in 
the late G1 phase of serum-stimulated IMR-90 cells leads 
to inhibition of the CAK activity, CDK2 phosphorylation 
and CDK2 activation. The inhibitory effects mediated by 
PKC involve suppression of the mRNA levels of both 
CDK7 and cyclin H. To our knowledge this is the first 
report describing down-regulation of CAK by a negative 
cell cycle regulator. 
48 h and washed extensively with DMEM/BSA as de- 
scribed [8]. 
2.3. Measurement of the CDK2 kinase activity and analy- 
sis of phosphorylation state of CDK2 
CDK2-associated histone H1 kinase activity was mea- 
sured as described in detail previously, by using a poly- 
clonal antibody raised against the carboxyl terminal se- 
quence of human CDK2 [8]. Phosphorylation state of 
CDK2 was analyzed as follows. Quiescent cells in 60-mm 
dishes were incubated in the presence or absence of 10% 
fetal calf serum and PDBu (10 -7 M) for 16 h. Then cells 
were washed twice with phosphate-free Eagle's minimal 
essential medium and further incubated in the same medium 
containing [32p]orthophosphate (Du Pont-New England 
Nuclear) (100 /xCi/ml) for 4 h, in the continued presence 
or absence of 10% dialyzed, phosphate-free f tal calf 
serum [29] and PDBu. CDK2 was then immunoprecip- 
itated from labeled cells as described before [8], separated 
on 12% sodium dodecylsulfate-polyacrylamide gel lec- 
trophoresis (SDS-PAGE) and transferred onto Immobilon-P 
membrane (Millipore). CDK2 was probed with the anti- 
CDK2 polyclonal antibody and visualized by alkaline 
phosphatase-conjugated secondary antibody (Zymed) [8]. 
Radioactivity incorporated into CDK2 was then analyzed 
by Fuji BAS 2000 Bio-Image Analyzer [8]. 
2. Materials and methods 2.4. Measurement of the CAK kinase activity 
2.1. Cell culture 
IMR-90 cells are human diploid fibroblasts derived 
from fetal lung. They were obtained from the Japanese 
Cancer Research Resources Bank and maintained at sub- 
confluent state in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% fetal calf serum (GIBCO) as 
described previously [29]. Before each experiment cells 
were grown to confluence and made quiescent by culturing 
in DMEM containing 0.2% bovine serum albumin (Sigma) 
(DMEM/BSA) for 48 h. 
2.2. Measurement of [3H]thymidine incorporation into 
DNA 
Quiescent cells in 48-well plates were stimulated with 
10% fetal calf serum in fresh DMEM and pulse-labeled 
with [methyl-3H]thymidine (Du Pont-New England Nu- 
clear) (2 /zCi/ml) during the last 1 h of various length of 
incubations. In some wells PDBu (10 -7 M) (Sigma) was 
added at indicated time points. Radioactivity incorporated 
into acid-precipitable material was counted as described 
previously [29]. For down-regulation f cellular PKC, cells 
were pretreated with 1 /zM of PDBu in DMEM/BSA for 
A rabbit polyclonal antibody was raised against a key- 
hole limpet hemocyanine-conjugated synthetic peptide cor- 
responding to the carboxyl terminal sequence of mouse 
CDK7 (SGRPVTPPRTANPPKKR) [20]. The antibody 
specifically recognized mouse and human CDK7 of ap- 
prox. 40 kDa. CDK7 was immunoprecipitated from cell 
lysate by the antibody (IgG fraction) according to the 
method described for immunoprecipitation f CDK2 [8]. 
The CAK kinase activity of the immunoprecipitate was 
measured in vitro by using recombinant human CDK2 as a 
substrate, which was produced in Sf9 insect cells. A 
full-length uman CDK2 cDNA was isolated from cDNA 
library prepared from SV40-transformed WI-38 cells 
(VA13, subline 2RA) and ligated downstream of the poly- 
hedrin promoter of pVL1393. Sf9 cells were co-transfected 
with human CDK2 cDNA-carrying pVLI393 and Bac- 
ulovirus DNA (BaculoGold, PharMingen) by the lipofectin 
method. CDK2 protein produced in Sf 9 cells was purfied 
as described [30]. The phosphorylation reaction was per- 
formed at 32°C for 15 min in 25 /xl of reaction mixtures 
containing recombinant human CDK2 (2 /xg), 2.5 mM 
ATP, 4 ~Ci of [y-32p]ATP (Du Pont-New England Nu- 
clear), 1 mM dithiothreitol, 10 mM MgC12 and 25 mM 
Tris-HC1 (pH 7.5). The reaction was terminated by adding 
l0 /xl of 4 × Laemmli's ample buffer, followed by boil- 
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Fig. 1. The effects of serum and PDBu on [3H]thymidine incorporation i to DNA of IMR-90 human diploid fibroblasts. (A) Serum stimulation i duces the 
initiation of DNA synthesis after a lag period (G1 phase) of approx. 12 h. Quiescent cells were incubated with 10% fetal calf serum for indicated time 
periods and pulse-labeled with [3H]thymidine during the last 1 h of incubations. (B) Addition of PDBu either together with (0 ° ~ ) or 5 h after (5 ° ~ ) 
serum stimulation early completely inhibits serum-induced DNA synthesis. Quiescent cells were incubated with or without serum and PDBu (10-7 M) as 
indicated for 22 h and pulse-labeled with [3H]thymidine during the last 1 h. Data represent the means -t- S.E. of three determinations 
ing for 5 min. Phosphorylated CDK2 was separated on 
12% SDS-PAGE and autoradiographed. Radioactivity in- 
corporated into CDK2 was quantitated by using Fuji BAS 
2000 Bio- Image Analyzer. 
2.5. Northern blot analysis of  CDK7 (MO15), CDK2, 
cyclins A, E and H 
Nothern blot analysis was performed as described previ- 
ously [8,28]. Ten micrograms of total cellular RNA was 
prepared  by  the  guan id ine  i so th io  - 
cyanate /pheno l /ch lo ro form extraction method [31], sepa- 
rated by fo rmaldehyde/1 .0% agarose gel electrophoresis 
and transferred to a ny lon membrane  (Hybond 
N)(Amsterdam). The probes for human CDK2, cyclin A 
and cyclin E were described elsewhere [8,28]. The 560-base 
fragment (nucleotides 31-590 when A of  the initiation 
codon ATG was numbered as 1) of  human CDK7 (MO15) 
cDNA and the 475-base fragment (nucleotides 19-493) of  
human cyclin H cDNA were obtained with the polymerase 
chain reaction amplif ication method. Each probe was la- 
beled to a specific activity of 2 to 7 × l08 cpm/mg with 
4-  
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Fig. 2. The addition of PDBu 5 h, but not 16 h, after serum stimulation completely inhibits the activation of CDK2 kinase. Quiescent cells were stimulated 
with serum and treated with or without PDBu (10 -7 M) as indicated. After 21 h CDK2 was immunoprecipitated from cell lysate (200 /.Lg of protein) and 
the CDK2 kinase activity was measured in vitro with histone HI as a substrate. The position of phosphorylated histone HI is indicated in the right. 
Numbers on the left, molecular mass in kDa. 
152 K. Hamada et al. / Biochimica et Biophysica Acta 1310 (1996) 149-156 
[c~-32P]dCTP (Du Pont-New England Nuclear) by the 
random priming method. Hybridization was performed, 
membranes washed and autoradiographed as described 
[8,28]. The radioactivity of corresponding bands was quan- 
titated by the Fuji BAS 2000 Bio-Image analyzer. After 
stripping radioactive probes off the membrane, the mem- 
brane was rehydrized with 32p-labeled glyceraldehyde-3- 
phosphate dehydrogenase (GAPDH) cDNA probe, the re- 
suits being used as an internal control. 
3. Resul ts  and d iscuss ion 
Stimulation of quiescent IMR-90 cells with fetal calf 
serum leads to initiation of DNA synthesis after the G1 
phase of approx. 12 h (Fig. 1A). The addition of PDBu 
(10 -7  M) ,  either at 0 time point together with serum or 5 h 
after serum stimulation, similarly results in nearly com- 
plete suppression of DNA synthesis measured at 22 h (Fig. 
1B). If PDBu is added 16 h after serum stimulation, i.e., 
after cells have entered the S phase, the inhibitory effect of 
PDBu is markedly reduced (Fig. 1B). These results indi- 
cate that the major target of PDBu action resides in the late 
G1 phase. Differently from certain types of cells such as 
Swiss 3T3 fibroblasts [23,24], PDBu does not at all stimu- 
late DNA synthesis in IMR-90 cells, either alone or in 
combination with serum growth factors (Fig. 1B). The 
growth inhibitory effect of PDBu is totally abolished in 
PDBu-pretreated, PKC-down-regulated cells (Table 1), 
suggesting that the effect of PDBu is mediated by a 
down-regulation-sensitive isoform(s) of PKC. 
PDBu-induced inhibition of DNA synthesis is closely 
associated with inhibition of CDK2 activation. Thus, as 
shown in Fig. 2, the addition of PDBu (10  -7 M)  5 h after 
serum stimulation completely suppresses erum-induced 
increase in the CDK2 activity, whereas its addition 16 h 
after serum stimulation results in only partial inhibition. 
PDBu does not have any direct effect on the CDK2 
Table 1 
PDBu-induced inhibition of DNA synthesis is abolished in PKC-down- 
regulated cells 
Control PKC-down-regulated 
None 660 + 40 1220 _+_ 10 
Serum 5770 + 230 7660 J: 1100 
Sernm + PDBu 930+70 7800~ 1000 
Data are cpm/well. 
Quiescent cells were pretreated with either 1 /a,M of PDBu (PKC-down- 
regulated) or 0.1% dimethylsulfoxide (Control) for 48 h, washed exten- 
sively, and then incubated in the presence or absence of 10% fetal calf 
serum and PDBu (10 -7 M) for 22 h. Cells were labeled with [3H]thymi- 
dine during the last 1 h. Data represent means + S.E. of three determina- 
tions. 
activity in vitro when added to kinase assay tubes [8]. As 
for [3H]thymidine incorporation experiments, the in- 
hibitory effect of PDBu on CDK2 activation is nearly 
totally abolished in phorbol ester-pretreated, protein kinase 
C-down-regulated cells. Since it is now established that 
CDK2 activation is a critical event for the G1/S cell cycle 
transition [9-13], it is rational to conclude that PKC-medi- 
ated suppression of CDK2 activation is, at least in part, 
responsible for failure of PDBu-treated cells to enter the S 
phase. 
To study the molecular mechanism by which PKC 
mediates inhibition of CDK2 activation, we first examined 
the protein level and the phosphorylation state of CDK2. 
Shown in Fig. 3 are immunoblots and autoradiograms of 
CDK2 immunoprecipitated from cells metabolically la- 
beled with [32P]orthophosphate. C lls were serum-stimu- 
lated, treated with or without PDBu 6 h later, and then 
labeled with 32p during the final 4 h of total 20 h incuba- 
tions. Quiescent cells express a moderate amount of 33 
kDa CDK2 protein. Serum stimulation for 20 h leads to an 
emergence of the second band with a higher mobility, as 
well as a slight increase in the amount of the major 33 kDa 
band. It has previously been shown that CAK-mediated 
Western  blot  
I I 
i 
30- -  
Serum - + + 
PDBu - - 6" -  
32p autorad iography  
I I 
p33 cdk2 
- -  + 4- 
~ 60~ 
Fig. 3. Western blot and autoradiogram of CDK2 immunoprecipitated from 32 P-labeled cells. Quiescent cells were incubated in the presence or absence of 
serum and PDBu for a total of 20 h as indicated. During the last 4 h cells were metabolically abeled with [32p]orthophosphate in phosphate-free medium. 
CDK2 was immunoprecipitated, separated on 12% SDS-PAGE and transferred to a membrane. After Western blot analysis with anti-CDK2 antibody, the 
membrane was exposed to a Fuji BAS 2000 IP plate and radioactivity detected. 
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Fig. 4. Left: time-dependent changes in the CAK kinase activity in serum-stimulated IMR-90 cells. Quiescent cells were incubated with 10% fetal calf 
serum for indicated periods of time, CAK was then immunoprecipitated from 230/xg of cellular protein and the kinase activity was measured in vitro with 
recombinant human CDK2 as a substrate. The position of phosphorylated CDK2 is indicated on the right. Numbers on the left, molecular mass in kDa. 
Right: CAK kinase activity is not recovered when the antibody has been immunoabsorbed by preincubation with the antigen peptide. 
phosphorylation f CDK2 at Thrl60 causes increased mo- 
bility on SDS-PAGE, and that substitution of Thrl60 to 
Ala abolishes the CAK-mediated phosphorylation a d the 
mobility shift on SDS-PAGE [32]. In fact, serum stimula- 
tion causes stimulation of 32 P-labelling of the faster mi- 
grating band of CDK2 (Fig. 3). Therefore, the second band 
with a higher mobility most likely represents Thrl60-phos- 
phorylated form of CDK2. The addition of PDBu 6 h after 
serum stimulation results in complete disappearance of the 
second band on immunoblot and a marked reduction in the 
32p radioactivity incorporated into this band, without a 
detectable change in the amount of the major 33 kDa band 
on immunoblot (Fig. 3). The results indicate that activating 
phosphorylation f CDK2 at Thrl60 [16-18] is suppressed 
by PKC activation. In addition, Fig. 3 also shows that 
serum stimulation leads 1:o increased phosphorylation of
CDK2 at sites other than Thrl60, as demonstrated by 
phosphorylation f the major 33 kDa band, and that PKC 
activation inhibits this process as well. 
Since it has now been established that phosphorylation 
of CDK2 at Thrl60 is specifically mediated by CAK 
[16-18], the results suggest that PKC stimulation leads to 
inhibition of the CAK activity. To evaluate this possibility, 
we raised a polyclonal antibody against CDK7, the cat- 
alytic subunit of CAK, and studied changes in the CAK 
kinase activity in response to serum stimulation and PDBu 
treatment in IMR-90 cells. Shown in Fig. 4 (left) are 
changes in the CAK activity in serum-stimulated IMR-90 
cells. Quiescent cells show a moderate l vel of basal CAK 
activity, as reported previously for other cell lines [33,34]. 
Differently from them, however, serum stimulation of 
IMR-90 cells results in a moderate, sustained increase in 
4 m 
67-  
43-  
30 -  
20.1 - -  
14.4 - 
Serum 
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~-- CDK2 
Control I + PDBu 
+ in vitro 
5°~ 
4--- C Dt~9_ 
Fig. 5. Left: addition of PDBu 5 h after serum stimulation i hibits serum-induced increase in the CAK kinase activity. Quiescent cells were incubated with 
or without serum and PDBu (10 -.7 M) for a total of 18 h, and then the CAK activity was measured. Right: PDBu does not inhibit the CAK kinase activity 
when directly introduced into a ldnase assay tube. 
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Fig. 6. Northern blot analysis of changes in the mRNA levels of CDK7 and cyclin H, the catalytic and the regulatory subunit of CAK, respectively. 
Quiescent cells were stimulated with serum for indicated time periods (h) and 10 /xg each of total cellular mRNA was analyzed. GAPDH was adopted as 
an internal control. 
the CAK activity. Thus, the CAK activity starts to increase 
within 5 h of serum stimulation, when 1.3-fold stimulation 
over the basal level is observed. The CAK activity reaches 
the plateau value of approximately 1.5-fold over the basal 
level by 10 h, which is sustained for up to 22 h of 
observations. Preincubation of the anti-CDK7 antibody 
(IgG fraction) with the antigen peptide completely abol- 
ishes the CAK kinase activity (Fig. 4, right). A sustained 
increase in the CAK activity after serum stimulation of 
quiescent cells has also been reported very recently for 
Swiss 3T3 fibroblasts [35]. As shown in Fig. 5 (left), if 
PDBu (10 -7 M) is added 5 h after serum stimulation, it
inhibits serum-stimulated increase in the CAK activity 
down to the basal level. Thus, the CAK activity 18 h after 
serum stimulation without PDBu treatment is 148-t-6% 
(mean + S.E. of four determinations; P < 0.01 as com- 
pared with quiescent cells by Students' t-test), whereas the 
CAK activity in serum-stimulated, PDBu-treated cells (97 
+ 3% of the basal level in quiescent cells) is not signifi- 
cantly different from that in quiescent cells. The addition 
of PDBu directly to kinase assay tubes has no effect on the 
CAK activity in vitro (Fig. 5, right). Very recently, it has 
Serum 
PDBu 
Control 
+ -I- 
5o~ 
PKC-D 
+ + 
5 ° _ 
CDK7 
Cyclin H 
GAPDH 
Fig. 7. Addition of PDBu 5 h after serum stimulation potently inhibits increases in the mRNA levels of both CDK7 and cyclin H in control, but not 
PKC-down-regulated (PKC-D), IMR-  90 cells. Cells were preincubated in DMEM/BSA containing either 0.1% dimethylsulfoxide (control) or 1 /xM 
PDBu (PKC-D) for 48 h and at the same time made quiescent. Cells were then extensively washed and further incubated in the presence or absence of 
serum and PDBu (10 -7 M) for 22 h. GAPDH was adopted as an internal control. 
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been demonstrated that CAK (CDK7/cyclin H complex) 
is associated with a general transcription factor IIH (TFIIH) 
and is responsible for the TFIIH-associated kinase activity 
that phosphorylates anessential carboxyl terminal domain 
of the RNA polymerase II large subunit, which is a critical 
step that occurs during initiation of transcription [36-39]. 
It is also shown that MOI5 is directly involved in TFIIH- 
associated nucleotide xcision repair activity [36]. Indeed, 
CAK activity is reported to be recovered as two major 
peaks with different mobilities after gel filtration proce- 
dure [17]. It is intriguing to speculate that PDBu treatment 
of IMR-90 cells specifically down-regulates a subpopula- 
tion of CAK that is responsible for phosphorylation of
CDK family kinases, without affecting a subpopulation 
that associates with TFIIH. In fact, in spite of the complete 
cell cycle arrest, serum-induced increases in the cellular 
protein content are barely affected by PDBu treatment in 
IMR-90 cells, suggesting specific inhibitory effects of 
PDBu on the cell cycle machinery but not on housekeep- 
ing functions. Further studies are required to elucidate this 
point. 
We further studied the effects of serum and PDBu on 
the mRNA level of CDK7 and cyclin H, the catalytic and 
the regulatory subunits of CAK, respectively (Figs. 6 and 
7). In serum-stimulated IMR-90 cells, the message level of 
both CDK7 and cyclin H nearly doubles over the basal 
quiescent level by 4 h, and stays at this level for up to 20 h 
(Fig. 6). The mRNA level of GAPDH, adopted as an 
internal control, shows an 1.2-fold increase only after 12 h, 
and reaches the maximal level of 1.5-fold increase after 20 
h. The addition of PDBu 5 h after serum stimulation 
completely cancels out the stimulatory effects of serum on 
both CDK7 and cyclin H mRNA levels, but not that of 
GAPDH (Fig. 7). The selective inhibition by PDBu treat- 
ment on both CDK7 and cyclin H mRNA levels are 
markedly attenuated in PKC-down-regulated cells, suggest- 
ing that this inhibition is mediated by a down-regulation- 
sensitive PKC isoform(s). These results indicate that PKC 
activation in the late G1 phase of serum-stimulated cells 
leads to inhibition of the CAK activity to the basal unstim- 
ulated level, at least in part through suppression of serum- 
induced increases in the mRNA level of both the catalytic 
and the regulatory subunits of CAK. 
We have previously shown in human umbilical vein 
endothelial cells that PKC-mediated inhibition of CDK2 
activation is associated with complete suppression of in- 
creases in the mRNA level of the partner cyclin molecules, 
cyclins A and E, but not CDK2 itself [8,28]. The same set 
of changes are also observed in IMR-90 cells (data not 
shown). The results strongly suggest that molecular mech- 
anisms underlying PKC-mediated cell cycle arrest are sim- 
ilar, if not identical, among different cell types. CAK 
phosphorylates CDK2 in vitro equally well whether or not 
cyclin A is present [17]. However, activation of CDK2 as a 
protein kinase absolutely requires complex formation with 
a partner cyclin molecule in addition to Thrl60 phospho- 
rylation [16,17]. Although the exact sequence of in vivo 
activation events of CDK2 (first cyclin binding and then 
Thrl60 phosphorylation r vice versa) is not well under- 
stood, the present study provides compelling evidence that 
two steps of CDK2 activation, cyclin A induction and 
CAK-mediated phosphorylation f CDK2, are both com- 
pletely suppressed by PKC activation in the late G1 phase, 
a time frame when the two events of the CDK2 activation 
process are close to, or are being turned on. It is possible, 
however, that PDBu-mediated down-regulation f cyclin A 
mRNA level is the result of PKC-mediated cell cycle 
arrest. With this respect, it is of interest o test whether 
PKC activation in the late G1 phase causes any increase in 
the level of a CDK inhibitor. Recently it was shown in a 
macrophage cell line that activation of protein kinase A 
leads to cell cycle arrest through induction of the CDK 
inhibitor p27Kipl, which binds to CDK4 and inhibits CAK- 
mediated phosphorylation f CDK4 in the face of normal 
CAK activity [40]. However, we failed to detect any 
increase in the protein level of p27Kipl upon PDBu treat- 
ment. We are now under investigation regarding potential 
involvement of other CDK inhibitors in PKC-mediated G1 
arrest. 
Our results strongly suggest that down-regulation-sensi- 
tive isoform(s) of PKC mediates the inhibitory effects of 
PDBu on the CAK-CDK2 cascade. In studies with human 
umbilical vein endothelial cells, we have found that PKC- 
c~, -6, -e and ~" are present in this cell type and that the 
first three isoforms are sensitive to down-regulation proce- 
dure [28]. However, the same set of PKC isoforms are 
present in Swiss 3T3 fibroblasts, in which PDBu induces 
activation of CDC2 and initiation of DNA synthesis [41]. 
Therefore it remains unknown at present which isoform(s) 
is responsible for PDBu-induced cell cycle arrest in en- 
dothelial cells and IMR-90 fibroblasts. Further studies are 
required to elucidate molecular mechanism(s) of PKC- 
mediated cell cycle regulation, which involves modulation 
of the message level of molecules constituting the cell 
cycle machinery. 
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